Clinical Features and Management of COVID-19-Associated Hypercoagulability

Card Electrophysiol Clin. 2022 Mar;14(1):41-52. doi: 10.1016/j.ccep.2021.10.005. Epub 2021 Oct 30.


COVID-19 is an acute respiratory disease of viral origin caused by SARS-CoV-2. This disease is associated with a hypercoagulable state resulting in arterial and venous thrombotic events. The latter are more frequent, especially in patients who develop a severe form of the disease and are associated with an increased mortality rate. It is therefore essential to identify patients at higher risk to initiate antithrombotic therapy. Hospitalized patients treated with treatment dose of anticoagulants had better outcomes than those treated with prophylactic dose. However, several trials are ongoing to better define the therapeutic and prevention strategies for this insidious complication.

Keywords: Antithrombotic therapy; Arterial thrombosis; COVID-19 coagulopathy; Hypercoagulability; Venous thromboembolism.

Publication types

  • Review

MeSH terms

  • Anticoagulants / therapeutic use
  • COVID-19* / complications
  • Humans
  • SARS-CoV-2
  • Thrombophilia* / complications
  • Thrombophilia* / drug therapy
  • Thrombosis* / drug therapy


  • Anticoagulants